MAPT siRNA therapeutic (Eli Lilly and Company)

N/A

Report date: 2025/12/08 17:13:58
NME

Base Information

Drug NameMAPT siRNA therapeutic (Eli Lilly and Company)
Drug Alias NameMAPT siRNA (Eli Lilly and Company)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsNeurodegenerative Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsNeurodegenerative Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A